Satoh K, Imaizumi T, Yoshida H, Hiramoto M, Konta A, Takamatsu S
Department of Pathologic Physiology, Hirosaki University, Japan.
Acta Neurol Scand. 1991 Feb;83(2):99-102. doi: 10.1111/j.1600-0404.1991.tb04657.x.
The plasma level of 11-dehydrothromboxane B2 (11-dehydroTXB2) is free from artifactual increase during blood sampling, and it can be reliable indicator of TXA2 production in vivo. We have estimated plasma 11-dehydroTXB2 in patients with ischemic stroke. Subjects studied were 29 patients with cerebral thrombosis (62 +/- 9 years old) and 41 healthy controls (61 +/- 7 years old). Plasma 11-dehydroTXB2 and TXB2 were determined by radioimmunoassay. Plasma 11-dehydroTXB2 levels in patients and controls were 5.4 +/- 2.5 and 1.8 +/- 0.9 pg ml, respectively, and the difference was significant (p less than 0.001). Plasma TXB2 also was higher in patients than in controls: 401 +/- 61 vs 311 +/- 51 pg/ml (p less than 0.05). However, the 11-dehydroTXB2 was found to be a more effective parameter to distinguish between stroke patients and controls. Estimation of plasma 11-dehydroTXB2 levels is a reliable method to detect platelet hyperfunction in stroke patients.
11-脱氢血栓素B2（11-dehydroTXB2）的血浆水平在采血过程中不会出现人为升高，它可以作为体内血栓素A2（TXA2）生成的可靠指标。我们对缺血性中风患者的血浆11-脱氢血栓素B2水平进行了评估。研究对象为29例脑血栓患者（62±9岁）和41名健康对照者（61±7岁）。采用放射免疫分析法测定血浆11-脱氢血栓素B2和血栓素B2（TXB2）。患者和对照者的血浆11-脱氢血栓素B2水平分别为5.4±2.5和1.8±0.9 pg/ml，差异具有统计学意义（p<0.001）。患者的血浆TXB2水平也高于对照者：401±61 vs 311±51 pg/ml（p<0.05）。然而，发现11-脱氢血栓素B2是区分中风患者和对照者的更有效参数。测定血浆11-脱氢血栓素B2水平是检测中风患者血小板功能亢进的可靠方法。
